GLP-1 weight loss patches reduced cravings during a month-long trial but caused no weight loss and remain unapproved by the ...

Phase 3 clinical trial results (TRANSCEND-T2D-1) published in The Lancet report that retatrutide, an investigational ...

The share of U.S. adults taking GLP-1 medications to lose weight has reached a record 11%. That's about 40 million people—as ...

The percentage of American adults who are currently taking a GLP-1 drug for weight loss is 11%, according to a new survey ...

GLP-1 medications like Ozempic and Wegovy are changing the conversation around weight loss. And to be clear, they work. Clinical data shows users can lose significant body weight, often in the 10 to ...

There is no shortage of headlines about GLP-1 medications. Originally developed to manage blood sugar levels, these medications are now widely known for promoting weight loss. Alongside their rapid ...

Use of GLP-1 weight-loss drugs in the U.S. has tripled since 2024.

Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and ...

For the first time, Medicare will cover GLP-1 drugs prescribed solely for weight loss for eligible beneficiaries at a $50 ...

A systematic review and meta-analysis finds that GLP-1-based treatments drive clinically meaningful weight loss mainly through fat reduction, but experts warn that preserving muscle remains essential ...

Side effects like nausea, vomiting, diarrhea and constipation are common soon after starting GLP-1s or increasing the drug’s dosage. A nutrient-dense diet and regular exercise are essential when on a ...

GLP-1 insurance coverage for weight loss varies greatly by plan type. Private insurance often excludes these drugs entirely, while Medicare is opening pathways for coverage. Still, access depends on ...